Search results
Results from the WOW.Com Content Network
Several treatment options exist for recurrent C. difficile infection. For the first episode of recurrent C. difficile infection, the 2017 IDSA guidelines recommend oral vancomycin at a dose of 125 mg four times daily for 10 days if metronidazole was used for the initial episode. If oral vancomycin was used for the initial episode, then a ...
Clostridioides difficile (syn. Clostridium difficile) is a bacterium known for causing serious diarrheal infections, and may also cause colon cancer. [4] [5] It is known also as C. difficile, or C. diff (/ s iː d ɪ f /), and is a Gram-positive species of spore-forming bacteria. [6]
In early 2008, a noninferiority study versus vancomycin or metronidazole for Clostridioides difficile associated diarrhea (CDAD) found that about half of the patients in the tolevamer group did not complete the treatment, versus 25% in the vancomycin and 29% in the metronidazole groups. CDAD recurrence in patients reaching clinical success was ...
Any event listed by the vaccine manufacturer as a contraindication to subsequent doses of the vaccine. Any event listed in the Reportable Events Table that occurs within the specified time period after vaccination. The data are stored electronically by the CDC in the Vaccine Safety Datalink (VSD).
FMT is an effective treatment for Clostridioides difficile infection (CDI). [3] [4] [5] For recurrent CDI, FMT is more effective than vancomycin alone, and may improve the outcome after the first index infection. [3] [5] [6] Side effects may include a risk of infections, therefore the donor should be screened for pathogens. [7]
A drug of last resort (DoLR), also known as a heroic dose, [1] is a pharmaceutical drug which is tried after all other drug options have failed to produce an adequate response in the patient. Drug resistance , such as antimicrobial resistance or antineoplastic resistance , may make the first-line drug ineffective, especially in case of ...
Mechanisms underlying the cause of reactogenicity symptoms. In clinical trials, reactogenicity is the capacity of a vaccine to produce common, "expected" adverse reactions, especially excessive immunological responses and associated signs and symptoms, including fever and sore arm at the injection site.
The toxins are the main virulence factors produced by the gram positive, anaerobic, [2] Clostridioides difficile bacteria. The toxins function by damaging the intestinal mucosa and cause the symptoms of C. difficile infection, including pseudomembranous colitis. TcdA is one of the largest bacterial toxins known.